Answers are grounded in this paper and cite their sources.
Because Becker muscular dystrophy (BMD) is a heterogeneous disease and only few studies have evaluated adult patients, it is currently still unclear which outcome measures should be used in future clinical trials.
No takes yet. Share an insight, caveat, or question.
Wel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: